IASLC TTLC 2024 | How can ctDNA assess MRD and profile tumor types in lung cancer?

Bruna Pellini, MD, H. Lee Moffitt Cancer Center, Tampa, FL, comments on the role of circulating tumor DNA (ctDNA) as a biomarker to evaluate minimal residual disease (MRD) in patients with lung cancer. In the MERMAID-1 (NCT04385368) and MERMAID-2 (NCT04642469) trials, there were feasibility issues regarding the use of ctDNA, where not enough tumor tissue was available. Whilst tumor informed assays have evolved over time, additional research is needed for their use in clinical practice. Dr Pellini additionally highlights the utility of chemoimmunotherapy in this space. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.